Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Parenthetical) (Details) - SOD 2020 SOC2020 SOUS2020 |
12 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||
Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024 | 20.00% | |
Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical | 25.00% | 50.00% |
Percentage of exercisable instruments relating to the development of NTZ and the ACLF franchise | 15.00% | 15.00% |
Percentage of exercisable instruments relating to the NIS4 diagnostic technology | 15.00% | |
Percentage of exercisable instruments relating to development of the product pipeline of the company | 25.00% | |
Percentage of exercisable instruments relating to NI4 diagnostics technology | 25.00% |